Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well nivolumab and chemoradiotherapy works in treating
patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab,
may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the
combination of chemotherapy and radiation therapy and may prevent the cancer from spreading
when combined with nivolumab. Giving nivolumab and chemoradiotherapy may work better in
treating patients with stage II-IVB nasopharyngeal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sue Yom University of California, San Francisco
Collaborators:
Bristol-Myers Squibb National University Cancer Institute, Singapore